Regulatory Environment - All revenues are generated in the PRC, with operations conducted through Beijing Feitian, making the company highly sensitive to political, economic, and social conditions in China [23]. - The Chinese economy has experienced uneven growth, with a slowdown since 2021, which could affect discretionary spending and orders for Beijing Feitian's products [26]. - Beijing Feitian has received all requisite licenses and approvals from PRC authorities, including a Class III Medical Device Operation License, which is valid for five years [31]. - The company plans to renew its medical device licenses and business licenses in a timely manner before expiration [31]. - Any adverse changes in Chinese government policies or economic conditions could materially affect Beijing Feitian's operations and competitive position [26]. - The PRC government's oversight could result in material adverse changes in operations and the value of securities if additional permissions are required [36]. - Regulatory changes may increase competition or lower market entry barriers, potentially affecting Beijing Feitian's market position [40]. - The company does not currently manage foreign currency exposure through hedging transactions, which could impact financial results if international revenues increase [28]. - Uncertainties in the interpretation and enforcement of PRC laws may limit legal protections and affect business operations [33]. - Beijing Feitian is not subject to cybersecurity review as it does not possess personal data of over one million users and does not anticipate reaching that threshold in the foreseeable future [41]. - The company is not currently involved in any cybersecurity investigations, but future regulatory changes could subject it to enhanced scrutiny and potential penalties [79]. - The PRC Foreign Investment Law, effective January 1, 2020, replaced previous laws regulating foreign investment, introducing uncertainties regarding its interpretation and implementation [81]. - Foreign investments must comply with a "negative list" issued by the State Council, which may impact Beijing Feitian's operations if its market falls under restricted or prohibited categories [82]. - The Chinese government exerts significant control over business operations, which may lead to increased compliance costs and potential adverse effects on the value of Class A Ordinary Shares [84]. - Compliance with PRC advertising laws is crucial, and any non-compliance could result in government sanctions, affecting the company's financial condition [87]. Financial and Tax Considerations - The company believes it is not a PRC resident enterprise for tax purposes, but if deemed so, it would face a 25% enterprise income tax on worldwide income [54]. - Dividends paid to non-resident enterprises would incur a 10% withholding tax, and gains from the sale of Class A Ordinary Shares may also be taxed at 10% [55]. - If classified as a PRC resident enterprise, dividends to non-PRC individual shareholders could be taxed at 20% [56]. - The ability of Beijing Feitian to distribute dividends is contingent on its accumulated profits as per PRC accounting standards [58]. - PRC regulations may limit the company's ability to inject capital into its operating entity or distribute profits, potentially affecting business operations [59]. - Future loans or capital contributions to Beijing Feitian require approval and registration with governmental authorities, which may delay funding [62]. - The company may face challenges in complying with evolving foreign exchange regulations, impacting its financial condition and operations [61]. - The company may not be able to complete necessary registrations or obtain approvals for future financing activities, affecting liquidity [67]. - The company faces uncertainties regarding indirect transfers of equity interests in PRC resident enterprises by offshore subsidiaries, which may lead to tax obligations under SAT Bulletin 7 and SAT Bulletin 37 [68]. - Gains from indirect transfers may be subject to a 10% PRC enterprise income tax, with both transferor and transferee potentially facing penalties for non-compliance [70]. Market and Competitive Landscape - The company relies primarily on the commercialization of FTTPS to generate revenue, expecting a majority of future revenue from FTTPS sales [106]. - The TPS market for brachytherapy has 6 approved products in China, including 3 specifically for radioactive particle implantation, indicating significant competition [119]. - The company’s growth may be impacted by decreasing customer demand, increasing competition, and changes in government policies [105]. - The company’s ability to achieve market acceptance for FTTPS depends on the strength of its sales, marketing, and distribution organizations [111]. - The company’s success is contingent on the widespread adoption of radiotherapy and brachytherapy as cancer treatments [110]. - The company may face challenges in maintaining product quality and safety, which are critical to its success [115]. - Beijing Feitian's operations are significantly impacted by U.S.-China trade relations, with the U.S. announcing 100% tariffs on all Chinese imports effective November 1, 2025, which could disrupt supply chains and increase costs [130]. - The company faces potential legal liabilities related to medical device safety, which could adversely affect its financial condition and operational results [123]. Operational Risks - The company has not identified any material quality deficiencies in its operations or those of its suppliers as of the report date [117]. - The company has limited control over third-party suppliers, and any significant interruption in their operations could adversely affect Beijing Feitian's business operations and customer relationships [127]. - The payment structure used in customer arrangements may lead to fluctuations in operating cash flows, impacting the company's financial performance if customers do not adhere to payment terms [143]. - Beijing Feitian's ability to attract and retain customers is crucial for revenue growth, with a risk of losing existing customers if competitors offer better products or services [139]. - The company does not carry business liability insurance, exposing it to significant costs and business disruptions related to potential claims and lawsuits [125]. - The company is vulnerable to intellectual property infringement claims, which could disrupt operations and adversely affect financial results [148]. - The company plans to expand operations with new products and markets, increasing the risk of intellectual property litigation [149]. - As of the date of the report, Beijing Feitian has no valid patents for its 3D printing technology, which may lead to competitive disadvantages [152]. - The company has identified three material weaknesses in its internal control over financial reporting as of December 31, 2025, which could result in inaccuracies in financial statements [159]. - The lack of business liability or disruption insurance exposes the company to significant costs and operational risks [154]. Shareholder and Governance Issues - Mr. Jianfei Zhang controls approximately 94.24% of the combined voting power of the company's equity interests through Class B Ordinary Shares [169]. - The company is considered a "controlled company" under Nasdaq standards, exempting it from certain corporate governance requirements [170]. - The dual class share structure allows Class B Ordinary Shares to have 20 votes per share compared to 1 vote for Class A Ordinary Shares, potentially limiting influence on corporate matters for Class A shareholders [183]. - The company may experience extreme share price volatility due to its small public float, making it difficult for investors to assess the value of Class A Ordinary Shares [172]. - There is a risk of delisting from the Nasdaq Capital Market if the company fails to meet listing requirements, which could negatively impact the price of its securities [186]. - Shareholders may face difficulties in protecting their interests due to the company's incorporation under Cayman Islands law, which has less developed securities laws compared to the U.S. [176]. - The company may not have a majority of independent directors due to its status as a controlled company, potentially affecting shareholder protections [170]. - The trading price of Class A Ordinary Shares may fluctuate significantly, with low trading volumes leading to greater price volatility [173]. - The company may rely on exemptions from certain Nasdaq requirements in the future, which could affect corporate governance practices [178]. - The trading volumes of Class A Ordinary Shares are low, leading to significant price fluctuations and potential losses for investors [191]. - Substantial sales or perceived sales of Class A Ordinary Shares could adversely affect their market price and impair future capital raising efforts [192]. - The company does not currently intend to pay dividends on Class A Ordinary Shares for the foreseeable future, focusing instead on operations and expansion [198]. - The company is classified as an "emerging growth company," allowing it to take advantage of reduced reporting requirements and exemptions from certain regulations [206]. - The company expects increased legal and financial compliance costs after ceasing to qualify as an "emerging growth company" due to the requirements of the Sarbanes-Oxley Act [211]. - If the company is classified as a passive foreign investment company (PFIC), U.S. taxpayers holding Class A Ordinary Shares may face adverse tax consequences [199]. - The market price of Class A Ordinary Shares may be negatively impacted if securities or industry analysts do not publish favorable research or coverage [194]. - The company may face challenges related to short selling, which could drive down the market price of Class A Ordinary Shares [195]. - The board of directors has the authority to issue additional classes or series of preferred shares, which could adversely affect the rights of Class A Ordinary Shareholders [205]. Corporate Actions and Future Plans - The company engaged Frost & Sullivan Limited for an industry report on the PRC medical device industry, with projections that may not materialize [213]. - The company sold 100,000,000 Class A ordinary shares at a purchase price of $0.2 per share, representing a discount of approximately 51.7% compared to the market price of $0.4141 on March 25, 2026 [215]. - The issuance of shares in the March 2026 Private Placement will result in substantial dilution to existing shareholders and decrease earnings per share in future periods [217]. - The company underwent a series of corporate restructuring, including the incorporation of Pheton as a holding company on November 2, 2022, and the acquisition of Beijing Feitian on March 27, 2023 [218]. - The company acquired 51% of iTonic Corporation and 30% of Geri-Safe, Ltd., issuing a total of 7,000,000 Class A ordinary shares as part of these transactions [218]. - The company is currently not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share and has until April 20, 2026, to regain compliance [218]. - The Class A ordinary shares from the private placement are subject to a six-month lock-up period, which may lead to significant selling pressure once it expires [216]. - The company has a share reserve of 2,800,000 ordinary shares under its 2025 Equity Incentive Plan approved by the board of directors [218]. - The company has authorized share consolidations at a cumulative ratio of not more than 1:4,000 within a two-year period [218]. - The acquisition of iTonic Corporation included the issuance of warrants for up to 3,000,000 Class A ordinary shares, contingent on certain milestones [218]. - The company aims to establish a new standard of care in malignant tumor applications through its healthcare solutions [218].

Vehicle Reservations and Production Plans - Aptera Motors has amassed over 49,000 vehicle reservations since its inception in 2019[21]. - The company aims to commence low-volume production and deliver the first customer vehicles in 2026, contingent on securing additional financing[29]. - Vehicle reservations are fully refundable, meaning that the aggregate number of reservations may not accurately indicate future sales, potentially leading to lower-than-anticipated revenues[100]. - As of December 31, 2025, Aptera Motors had approximately 49,000 reservation holders for its solar electric vehicles[197]. Financial Performance and Capital Needs - The company completed its first follow-on capital raise as a publicly traded entity, raising approximately $9 million in gross proceeds in January 2026, followed by an additional $8.1 million from subsequent warrant exercises[21]. - The company has not yet generated revenue or profits from continuing operations and anticipates significant operating expenses in the near future[77][78]. - Aptera plans to raise additional capital through equity and debt financings, which may dilute existing stockholders[81][82]. - The initial low-volume production phase requires an estimated $45 million to $50 million in capital, while ramping to high-volume production will need an additional $140 million to $160 million[200]. - General, selling, and administrative expenses increased by 33% to $26.8 million in 2025, primarily due to higher stock-based compensation and increased legal and regulatory costs[206]. - Research and development expenses rose by 25% to $21.3 million in 2025, driven by a $3.9 million increase in stock-based compensation[210]. - The company has not commenced production or generated any revenue from vehicle sales, relying on future financing to achieve profitable operations[196]. Strategic Collaborations and Supply Chain - Aptera has secured a strategic collaboration with Chery New Energy for the supply of production parts, which includes a cash payment of $1 million and $5 million in Class B common stock[42]. - The company is dependent on a few suppliers for vehicle components, with some being single-source, which could adversely affect operations if suppliers fail to deliver on time or at acceptable quality levels[88]. - Ongoing industry-wide challenges, such as increased supplier lead times and semiconductor supply constraints, are expected to continue affecting the company's ability to obtain parts and may result in increased costs[90]. Regulatory and Compliance Challenges - The company is classified as a three-wheeled motorcycle and is working to comply with Federal Motor Vehicle Safety Standards[58][60]. - Regulatory compliance is a significant hurdle, with stringent standards for vehicle safety, fuel economy, and emissions control potentially delaying production launches[111]. - The company has received a subpoena from the SEC related to its securities offerings and is cooperating with the ongoing investigation[55][56]. Legal Issues and Risks - Zaptera USA, Inc. filed a complaint against Aptera Motors Corp. for design patent infringement and misappropriation of trade secrets, seeking damages and injunctive relief[53][54]. - The company is currently involved in litigation with Zaptera USA, Inc. regarding design patent infringement and misappropriation of trade secrets, which could materially harm its business[184]. - The company is currently involved in a patent infringement lawsuit, which could divert resources and delay production goals[119]. - An ongoing investigation by the Securities and Exchange Commission may lead to legal proceedings, potentially adversely affecting the company's business and financial condition[120][121]. Technological and Market Challenges - The competitive landscape includes established manufacturers with greater resources, which may hinder the company's ability to effectively compete and secure necessary capital[105]. - The company's success relies on consumer adoption of energy-efficient, solar-powered vehicles, which may be affected by developments in alternative technologies and low gasoline prices[110]. - Demand in the passenger vehicle industry is highly volatile, influenced by economic, political, and social conditions, which may adversely affect the company's financial condition[114]. - The company faces significant technological and legal barriers to entry, with uncertainties regarding whether vehicles will meet disclosed performance specifications after validation and testing[106]. Internal Control and Governance - The company identified two material weaknesses in internal control over financial reporting (ICFR) during the year ended December 31, 2023, which continued into 2024[159]. - The first material weakness involved accounting for stock-based compensation, leading to a restatement of the 2023 financial statements due to deficient controls over equity modifications[160]. - The second material weakness related to a lack of formalized accounting and financial reporting policies, contributing to inconsistent policy application and error risk[161]. - The company is developing a comprehensive accounting and financial reporting policies manual to address the identified weaknesses[161]. Stockholder and Corporate Structure - The dual class structure of the common stock results in directors, executive officers, and 5% stockholders controlling 83% of the voting power, limiting the influence of Class B common stockholders on corporate matters[139]. - As of December 31, 2025, directors and executive officers, along with holders of more than 5% of common stock, held 97% of the voting power, further concentrating control[139]. - The company has never declared or paid any cash dividends on its capital stock and does not intend to do so in the foreseeable future, which means returns on investment will depend solely on the appreciation of Class B common stock[136]. - The company anticipates retaining future earnings for business development and expansion, rather than distributing dividends to stockholders[136]. Facility and Manufacturing Plans - Aptera's Carlsbad assembly facility received foreign-trade zone designation in February 2026, allowing for deferred customs duties on imported components, enhancing gross margin potential[48]. - The principal executive office is located in Carlsbad, California, occupying approximately 77,000 square feet of leased space, with the lease expiring on March 31, 2028[179]. - The facility is designated for initial low-volume manufacturing of the Aptera vehicle, with plans to expand production capacity as market demand increases[181].

IPO and Fundraising - The company completed its IPO on October 15, 2024, raising gross proceeds of $50 million from the sale of 5,000,000 units at an offering price of $10.00 per unit[36]. - An additional $7.5 million was generated from the full exercise of the over-allotment option, bringing total proceeds to $57.5 million[36]. - A private placement of 254,375 units generated total proceeds of $2,543,750, with the sponsor agreeing to restrictions on transfer for 30 days post-initial business combination[37]. - A total of $57,787,500 from the IPO and private placement proceeds was deposited in a trust account for public shareholders, with specific conditions for fund release[38]. - The trust account initially holds $58,287,500, which includes approximately $1,868,750 for deferred underwriting discounts, assuming no redemptions occur[152]. - The company incurred $1,006,250 in underwriting discounts and $556,288 in other IPO-related costs[180]. - The underwriters are entitled to a deferred fee of 3.25% of the gross proceeds of the IPO, amounting to $1,868,750, payable upon closing of a business combination[198]. Regulatory Environment - The company has not received any regulatory objections from the China Securities Regulatory Commission (CSRC) regarding the IPO as of the report date[51]. - The company may face significant regulatory risks from the PRC government, which could impact its ability to conduct business combinations and operations in China[45]. - The company is subject to the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, which may impose additional compliance requirements[50]. - The PRC government has implemented new regulatory measures that could significantly impact business operations for companies with a majority of their operations in China, potentially leading to material changes in operations and a decline in share value[77]. - Recent regulatory actions include increased scrutiny on cybersecurity, anti-monopoly enforcement, and restrictions on foreign investments, which may adversely affect the ability to conduct business in China[78]. - The China Securities Regulatory Commission (CSRC) has introduced the Trial Administrative Measures for overseas securities offerings, which require compliance if certain criteria are met, including if 50% or more of the issuer's revenue comes from PRC domestic companies[82]. Business Combination Strategy - The merger agreement involves the acquisition of HZJL, with HZJL's shareholders receiving 35 million ordinary shares of Xpand Boom Technology, plus potential earn-out consideration of up to 20 million shares based on revenue targets[62]. - The transaction is subject to regulatory approvals and shareholder approvals, with a requirement for a registration statement to be declared effective by the SEC[63]. - The company intends to pursue targets focused on green and sustainable business, new energy, and cutting-edge technologies, primarily in North America, Europe, and the Asia Pacific regions[86]. - The target size for acquisitions is intended to be between $500 million and $2 billion, focusing on companies with significant revenue growth[98]. - The strategy includes targeting businesses in high-growth sectors such as green and sustainable businesses, new energy, and artificial intelligence applications[99]. - The initial business combination must involve target businesses with a fair market value of at least 80% of the trust account balance[112]. - The company intends to acquire 100% of the equity interest or assets of the target business, ensuring majority control[113]. Financial Performance and Concerns - For the year ended December 31, 2025, the company reported a net income of $1,573,962, primarily from interest income of $2,389,246[188]. - As of December 31, 2025, the company had cash of $37,174 and a working capital deficit of $382,105, raising substantial doubt about its ability to continue as a going concern[155]. - The company has not generated any operating revenue to date and will not until after completing its initial business combination[187]. - Management has determined substantial doubt about the company's ability to continue as a going concern through January 15, 2026, if an initial business combination is not completed[196]. - The company has no long-term debt, capital lease obligations, or operating lease obligations as of December 31, 2025[198]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem shares at a per-share price initially anticipated to be $10.05[132]. - Redemption rights will be limited to 20% of the shares sold in the IPO for any public shareholder acting in concert with others[134]. - Initial shareholders and officers will not have redemption rights for any ordinary shares owned by them[135]. - Shareholders may withdraw redemption requests at any time up to the vote on the proposed business combination[139]. - If the initial business combination is not approved, public shareholders who elected to redeem their shares will not be entitled to the pro rata share of the trust account[140]. - A total of 5,668,070 ordinary shares were tendered for redemption during the EGM held on November 20, 2025[142]. - The per-share redemption amount upon dissolution is estimated to be approximately $10.05, subject to claims from creditors which may reduce this amount[145]. Management and Governance - The management team has extensive experience in public companies and financial management, which is expected to aid in identifying suitable acquisition targets[69]. - The management team aims to create shareholder value by guiding emerging high-growth companies towards commercialization[106]. - The management team is well positioned to capitalize on acquisition opportunities in emerging markets driven by innovative technologies or novel business models[228]. - The audit committee is composed of three independent members, ensuring compliance with NASDAQ listing standards and SEC rules[230]. - Chengming Dou qualifies as an "audit committee financial expert" as defined by SEC rules, enhancing the committee's oversight capabilities[231]. - The audit committee is responsible for pre-approving all audit and non-audit services provided by independent registered public accounting firms[232]. - The nominating committee oversees the selection of board nominees, ensuring candidates have notable achievements and high ethical standards[233]. Due Diligence and Evaluation - The evaluation of prospective target businesses includes assessing financial performance, growth potential, and market alignment[99][102]. - The company has identified various parameters for evaluating target businesses, including innovative technologies and strong ESG standards[101][97]. - The due diligence process for evaluating HZJL included meetings with management, document reviews, and financial information assessments[104]. - The agreement's consummation is conditioned on various factors, including shareholder approval and SEC declaration of the Registration Statement as effective[122]. - HZJL's obligations to close the transaction depend on the Purchaser Parties' compliance with the agreement and no material adverse effects on them[123]. - The Purchaser Parties' obligations to close are contingent upon HZJL's compliance with the agreement and receipt of necessary governmental approvals[124].

IPO and Fundraising - The company completed its IPO on October 15, 2024, raising gross proceeds of $50 million from the sale of 5,000,000 units at an offering price of $10.00 per unit[36]. - An additional $7.5 million was generated from the full exercise of the over-allotment option, bringing total proceeds to $57.5 million[36]. - The private placement with Aurora Beacon LLC generated total proceeds of $2,543,750 from the sale of 254,375 private units[37]. - A total of $57,787,500 from the IPO and private placement proceeds was deposited in a trust account for public shareholders, with specific conditions for fund release[38]. - The trust account initially holds $58,287,500, which includes approximately $1,868,750 for deferred underwriting discounts[152]. - The company intends to use the funds held outside the Trust Account primarily for identifying and evaluating target businesses and related expenses[193]. Business Combination and Acquisition Strategy - The merger agreement involves the acquisition of HZJL, with HZJL's shareholders receiving 35 million ordinary shares of Xpand Boom Technology, plus potential earn-out consideration of up to 20 million shares based on revenue targets[62]. - The transaction is subject to regulatory approvals and shareholder approvals, with a requirement for a registration statement to be declared effective by the SEC[63]. - The initial business combination must involve target businesses with a fair market value of at least 80% of the trust account balance[112]. - The company intends to acquire 100% of the equity interest or assets of the target business, ensuring majority control[113]. - The target size for acquisitions is intended to be between $500 million and $2 billion, focusing on companies with significant revenue growth[98]. - The strategy includes targeting businesses in high-growth sectors such as green and sustainable businesses, new energy, and artificial intelligence applications[99]. - The management team aims to create shareholder value by guiding emerging high-growth companies towards commercialization[106]. - The company intends to pursue targets in green and sustainable business, new energy, and cutting-edge technologies, focusing on small cap companies in North America, Europe, and the Asia Pacific regions[86]. Regulatory Risks and Compliance - The company will not pursue business combinations with entities operating through variable interest entities (VIEs), which may restrict acquisition opportunities in China[42]. - The company may face significant regulatory risks from the PRC government that could impact its ability to conduct business combinations or operations in China[45]. - The company is subject to the Trial Administrative Measures by the CSRC, which could impose additional compliance requirements for overseas listings[50]. - The PRC government has implemented new regulatory measures that could significantly impact business operations for companies with a majority of operations in China, including potential material changes in operations and depreciation of share value[77]. - Recent regulatory actions by the PRC government include increased scrutiny on foreign investments and cybersecurity reviews, which may adversely affect the ability to conduct business combinations with PRC entities[78]. - The PRC government controls the conversion of Renminbi (RMB) into foreign currencies, which may restrict the ability of PRC subsidiaries to remit sufficient foreign currency for dividend payments[91]. - If classified as a PRC tax resident enterprise, dividends paid to overseas shareholders may be subject to a withholding tax of up to 10.0%[92]. Financial Performance and Projections - The company reported a net income of $1,573,962 for the year ended December 31, 2025, primarily from interest income of $2,389,246[188]. - The company has not generated any operating revenue to date and will not do so until after completing its initial business combination[187]. - As of December 31, 2025, the company had cash of $37,174 and a working capital deficit of $382,105[155]. - Management has determined substantial doubt about the company's ability to continue as a going concern through January 15, 2026, if an initial business combination is not completed[196]. - The company has no long-term debt, capital lease obligations, or operating lease obligations as of December 31, 2025[198]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem shares at a per-share price initially anticipated to be $10.05[132]. - Redemption rights will be limited to 20% of the shares sold in the IPO for any public shareholder acting in concert with others[134]. - Initial shareholders and officers will not have redemption rights for any ordinary shares owned by them[135]. - Shareholders may withdraw redemption requests at any time up to the vote on the proposed business combination[139]. - If the initial business combination is not approved, public shareholders who elected to redeem their shares will not be entitled to the pro rata share of the trust account[140]. - A total of 5,668,070 ordinary shares were tendered for redemption in connection with the EGM held on November 20, 2025[142]. - As of December 31, 2025, 1,548,345 shares were redeemed at approximately $10.55 per share, totaling $16,331,209[186]. Management and Governance - The management team has extensive experience in public companies and financial management, which is expected to aid in identifying suitable acquisition targets[69][70]. - The management team is well positioned to capitalize on acquisition opportunities in emerging markets driven by innovative technologies or novel business models[228]. - The audit committee is composed of three independent members, ensuring compliance with NASDAQ listing standards and SEC rules[230]. - Chengming Dou qualifies as an "audit committee financial expert" as defined by SEC rules, enhancing the committee's oversight capabilities[231]. - The audit committee is responsible for pre-approving all audit and non-audit services provided by independent registered public accounting firms[232]. - The nominating committee oversees the selection of board nominees, ensuring candidates have notable achievements and high ethical standards[233]. - The company has established clear hiring policies for employees of independent registered public accounting firms to maintain auditor independence[232].

Full Year 2025 Financial Highlights Virgin Galactic Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update ORANGE COUNTY, CALIFORNIA. – March 30, 2026 – Virgin Galactic Holdings, Inc. (NYSE: SPCE) ("Virgin Galactic" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. CEO Michael Colglazier said, "We completed pivotal milestones during the first quarter of 2026, and with assemb ...

Revenue and Profitability - Revenues for the year ended December 31, 2025, were $124,157, a 499% increase from $20,729 in 2024, primarily driven by AI Nose related programs [226] - Gross profit for 2025 was $102,911, compared to a gross loss of $(31,866) in 2024, reflecting the positive impact of the product mix change [230] - The operating loss for 2025 was $13,990,408, a slight increase from $13,841,204 in 2024, as the company continued to invest in growth strategies [236] - Net loss for 2025 was $14,771,012, a 1% decrease from $14,863,161 in 2024, due to reduced co-research and D&O insurance expenses [238] - The Company generated a net loss of $14,771,012 for the year ended December 31, 2025 [263] Costs and Expenses - The cost of revenues decreased to $21,246 in 2025 from $52,595 in 2024, attributed to a change in product mix [228] - Research and development (R&D) expenses were $7,749,772 in 2025, a decrease of 8% from $8,413,923 in 2024, due to reduced staffing expenditures [232] - Selling, general and administrative (SG&A) expenses increased by 18% to $6,343,547 in 2025 from $5,395,415 in 2024, driven by higher staffing and public relations costs [234] Cash Flow and Financing - As of December 31, 2025, the company had cash and cash equivalents of $417,353, down from $3,892,919 in 2024 [239] - Net cash used in operating activities decreased by 21% to $4,614,697 in 2025 from $5,808,267 in 2024, reflecting improved cash inflow from operating assets [240] - Cash received from financing activities decreased by $7,017,285, from $8,025,746 in 2024 to $1,008,461 in 2025 [243] - The Company repaid $1,000,000 to retire the Lee Note transaction in April 2025 and received $2,008,721 in proceeds from ATM transactions in 2025 [247] - The Company anticipates funding operations over the next twelve months through cash reserves, business revenues, and potential debt financing [248] - The Company entered into an At The Market Offering Agreement on May 31, 2024, with an aggregate offering price of $1,840,350 [249] - The Company sold an aggregate of 734,214 shares under the ATM facility, receiving $2,008,721 in net proceeds after deducting commissions and expenses [258] Future Outlook and Strategic Plans - The Company secured an initial commercial order of approximately $2.1 million for 1,400 AI Nose systems in semiconductor manufacturing, marking a significant step in commercialization [211] - The Company expects to allocate liquidity primarily toward advancing the AI Nose platform and supporting industrial deployments [260] - The Company may require significant cash to fund working capital and capital expenditures as it grows its commercial infrastructure [261] Asset Management - As of December 31, 2025, the Company had cash and cash equivalents of $417,353 and an accumulated deficit of $67,520,328 [262] - The Company performed an impairment testing for intangible assets related to VOC POCT products, concluding no impairment loss was recorded [270]

Financial Performance - Lexeo Therapeutics reported a net loss of $20.9 million or $0.27 per share for Q4 2025, compared to a net loss of $25.9 million or $0.78 per share for Q4 2024[11] - Total cash, cash equivalents, and investments were $246.6 million as of December 31, 2025, expected to fund operations into 2028[12] - Research and Development expenses decreased to $16.2 million for Q4 2025 from $18.4 million in Q4 2024, and for the full year, they were $63.8 million compared to $74.1 million in 2024[11] - General and Administrative expenses for Q4 2025 were $6.9 million, down from $9.0 million in Q4 2024, while for the full year, they increased to $45.5 million from $31.7 million in 2024[11] Clinical Development - The company initiated the submission of the final registrational trial design and statistical analysis plan for the SUNRISE-FA 2 pivotal study to the FDA in February 2026[3] - Interim clinical data for LX2006 showed improvements in cardiac structure and functional outcomes, including reduced left ventricular mass index (LVMI)[3] - Anticipated milestones for 2026 include FDA feedback on protocol submission expected in Q2 and initiation of the SUNRISE-FA 2 pivotal trial in the first half of 2026[8] Strategic Collaborations and Financing - Lexeo established a research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy[8] - The company executed a $154 million equity financing in October 2025 to advance its cardiac pipeline and support registrational readiness activities for LX2006[8] Leadership Changes - The leadership team was strengthened with the appointment of a new Chief Medical Officer, enhancing expertise in cardiovascular medicine[8]

Revenue Performance - Fathom Holdings reported total revenue of $420 million for 2025, reflecting a 25% year-over-year growth, driven by a 15% increase in total transactions[2]. - For Q4 2025, total revenue decreased by 1.2% to $90.6 million, down from $91.7 million in Q4 2024, primarily due to a decline in real estate transactions[5][7]. - Brokerage revenue for Q4 2025 was $84.9 million, a decrease of 3.2% compared to $87.7 million in Q4 2024[5][8]. - Mortgage revenue surged by 70% to $3.4 million in Q4 2025, up from $2.0 million in Q4 2024[5][8]. - Title revenue increased by 38.5% to $1.8 million in Q4 2025, compared to $1.3 million in Q4 2024[5][8]. - Revenue for the year ended December 31, 2025, was $420,477 million, a significant increase from $335,184 million in 2024, representing a growth of 25.4%[25]. Net Loss and Adjusted EBITDA - Fathom's net loss for Q4 2025 was $6.7 million, or $0.21 per share, compared to a net loss of $6.2 million, or $0.29 per share, in Q4 2024[9]. - Adjusted EBITDA for Q4 2025 was negative $2.6 million, an improvement from negative $2.9 million in Q4 2024, due to reduced operating expenses[10]. - Net loss for the year ended December 31, 2025, was $20,307 million, slightly improved from a net loss of $21,577 million in 2024[27]. - Adjusted EBITDA for the year ended December 31, 2025, was $(4,001) million, compared to $(5,710) million in 2024, indicating a reduction in operational losses[29]. Cash Flow and Financial Position - Cash used in operating activities for the year ended December 31, 2025, was $(20,536) million, compared to $(4,688) million in 2024, reflecting increased cash outflows[27]. - Cash and cash equivalents at the end of the period were $5,917 million, down from $7,390 million at the beginning of the period[27]. - The company reported a loss before income tax of $(20,222) million for the year ended December 31, 2025, compared to $(22,599) million in 2024[29]. - The company incurred $3,704 million in stock-based compensation for the year ended December 31, 2025, down from $8,839 million in 2024[29]. - The company’s principal payments on debt for the year ended December 31, 2025, were $(4,570) million, compared to $(602) million in 2024, indicating increased debt repayment[27]. Real Estate Transactions and Strategic Initiatives - For the full year 2025, real estate transactions increased by approximately 14.6% to 42,405, largely due to the acquisition of My Home Group in November 2024[11]. - Fathom Holdings announced strategic partnerships with ByOwner and Move Concierge to enhance service offerings and customer experience[12]. - The company plans to withhold guidance for Q1 2026, with intentions to release 2026 guidance in the second quarter earnings release[16]. Shareholder Information - The weighted average common shares outstanding for the year ended December 31, 2025, were 28,196,335, an increase from 20,244,255 in 2024[25]. - The company reported a loss (gain) on the sale of business of $922 million for the year ended December 31, 2025, compared to a gain of $(2,958) million in 2024[29].

Clinical Development and Trials - Annexon is advancing two late-stage registrational programs: tanruprubart for Guillain-Barré Syndrome (GBS) and vonaprument for geographic atrophy (GA) in dry AMD, targeting significant unmet medical needs[23]. - Tanruprubart has shown that approximately 90% of GBS patients treated improved by week 1, with more than twice as many achieving a normal state of health by week 26 in a Phase 3 trial[24]. - Vonaprument demonstrated a more than 70% reduction in the risk of 15-letter vision loss in the Phase 2 ARCHER trial, addressing the needs of over 8 million patients with GA[27]. - The ongoing Phase 3 ARCHER II trial for vonaprument has enrolled 659 patients, with topline data expected in Q4 2026[28]. - The Phase 1b trial of tanruprubart involved 50 GBS patients, demonstrating that the drug was well tolerated with no serious adverse events reported[59]. - The clinical development of tanruprubart has generated a robust data package, including a successful Phase 3 trial showing faster and more complete functional recovery versus placebo[56]. - The ongoing FORWARD study aims to support a broad label for tanruprubart in GBS, with initial data expected in 2026[76]. - A Phase 2 trial of tanruprubart in Huntington's Disease (HD) showed stabilization of disease progression over nine months, with 28 patients enrolled and safety data from all participants[101]. - In the ALS Phase 2a trial, 13 patients were treated for 12 weeks, showing rapid target engagement and better outcomes for those with higher baseline complement activation[102]. - ANX009, evaluated in a Phase 1b trial for Lupus Nephritis (LN), was well tolerated with sustained C1q inhibition, supporting its potential for chronic dosing[103][105]. Drug Designation and Regulatory Approvals - Tanruprubart has received orphan drug designation from both the FDA and EMA, and a Marketing Authorization Application was filed with the EMA in January 2026[25]. - An MAA for tanruprubart was filed with the EMA in January 2026, and it has received orphan designation from the EMA and Fast Track designation from the FDA[77]. - Orphan Drug designation is granted for drugs intended to treat rare diseases, defined as having a patient population of fewer than 200,000 individuals in the U.S.[155]. - A product with Orphan Drug designation is entitled to seven years of exclusivity upon receiving the first FDA approval for the designated disease[156]. - The FDA may grant priority review designation, which sets a target date for action on a BLA or NDA at six months after acceptance of the application[150]. - The FDA may approve a BLA or NDA with a Risk Evaluation and Mitigation Strategy (REMS) to manage known or potential serious risks associated with a medicine[149]. - The FDA requires substantial time and financial resources for the approval process of new drugs, including compliance with various regulations[134]. - The company must navigate the regulatory landscape, including submitting Investigational New Drug (IND) applications and obtaining approvals for clinical trials[139]. Financial Performance and Projections - The company reported a net loss of approximately $206.7 million for the year ended December 31, 2025, compared to a net loss of $138.2 million for 2024, resulting in an accumulated deficit of $917.4 million as of December 31, 2025[186]. - The company has incurred significant losses since its inception in March 2011, with no products approved for commercial sale and no revenue generated from product candidates[185]. - As of December 31, 2025, the company had capital resources of approximately $238.3 million, expected to fund planned operating expenses into the second half of 2027[188]. - The company anticipates continuing to incur significant losses for the foreseeable future as it develops product candidates and conducts clinical trials[186]. - The company has primarily financed operations through equity securities, with a current offering program allowing for up to $150 million in common stock sales[192]. Research and Development Focus - The company aims to leverage its C1q inhibition platform to develop disease-modifying medicines for neuroinflammatory diseases, enhancing efficacy and safety[40]. - The strategic focus includes expanding the targeted immunotherapy platform and exploring licensing agreements to accelerate development and commercialization[41]. - Annexon has established a strong scientific and clinical rationale for its pipeline, addressing significant unmet medical needs in neuroinflammatory diseases[35]. - Significant resources are required for product development, leading to prioritization among candidates, particularly focusing on tanruprubart in GBS and vonaprument in GA[193]. Market and Competitive Landscape - The company faces intense competition from various sources, including pharmaceutical and biotechnology companies, which may have greater financial resources and established market presence[130]. - There are currently no approved therapies for Guillain-Barré Syndrome (GBS) in the United States, with investigational products in development by other companies[131]. - Two treatments for Geographic Atrophy (GA) received FDA approval in 2023, while there are ongoing clinical trials for additional therapies targeting GA[132]. - Sanofi's Enjaymo was approved for Cold Agglutinin Disease (CAD) in February 2022, and there are ongoing clinical trials for other investigational agents[133]. Operational Challenges - The company currently relies on third-party contract manufacturers for the production of its drug candidates, as it does not own or operate manufacturing facilities[125]. - The company is in discussions with current manufacturers regarding the preparation of a Biologics License Application (BLA) in the near future, with a Marketing Authorization Application (MAA) filed in January 2026[127]. - The company plans to establish long-term supply agreements to ensure continuity in its supply chain and is considering alternative larger scale suppliers for certain portions of its supply chain[128]. - The company faces delays in enrolling patients in clinical trials, which may impact the integrity of subject data and clinical study endpoints[207]. - Increased rates of patient withdrawals from clinical trials due to health conditions have been observed, affecting overall trial outcomes[207]. - The company anticipates potential disruptions in clinical trial operations due to regulatory agency interruptions and supply chain issues[208]. Intellectual Property and Licensing - The patent portfolio includes 19 different patent families filed worldwide, with key patents covering methods of treating neurodegeneration and related conditions[110]. - The company is obligated to pay Stanford up to $675,000 in milestone payments under the exclusive licensing agreement, along with royalties on worldwide net sales[115]. - The company may face challenges in obtaining and maintaining intellectual property rights, which could materially impact its business[121]. Future Risks and Uncertainties - The company faces risks related to the successful development and regulatory approval of product candidates, which are currently in early clinical stages[200]. - Public health crises, such as the COVID-19 pandemic, have previously disrupted clinical trials and may continue to adversely affect business operations[205]. - The variability in quarterly and annual results makes future performance difficult to predict, potentially leading to stock price declines if expectations are not met[199]. - The company may need to relinquish rights to technologies or product candidates through collaborations if additional funds are sought[192]. - The company must comply with varying regulatory requirements across jurisdictions, which could complicate the approval process[215]. - There is a risk that product candidates may not be accepted as safe and effective by the medical community or third-party payors, affecting marketability[212].

Financial Performance - Ainos reported a revenue increase of approximately 499% year-over-year for 2025, reaching $124,157, compared to $20,729 in 2024[3][16] - The gross margin improved significantly to approximately 82.9% in 2025, up from a gross loss in 2024[3] - The company reported a net loss of $14,771,012 for 2025, compared to a net loss of $14,863,161 in 2024[16] - Total assets decreased to $20,871,108 in 2025 from $28,820,199 in 2024, while total liabilities remained relatively stable at $13,308,526[14] Operating Expenses - Total operating expenses, excluding share-based compensation, depreciation, and amortization, decreased by 9% year-over-year, while reported operating expenses increased by about 2%[3] Financing and Liquidity - Ainos secured a financing of New Taiwan Dollar 90 million (approximately USD $2,820,000) to enhance liquidity for ongoing operations and deployment execution[4] Deployment Plans - Ainos is targeting the deployment of approximately 200 AI Nose systems in front-end wafer fabrication facilities for technical validation in Q1 2026[7] - A three-year deployment plan includes approximately 1,400 AI Nose systems in semiconductor packaging and testing environments, with a budget of $2.1 million, expected to complete by Q2 2026[7] - Ainos aims to scale up to 20,000 systems in the semiconductor sector, subject to validation and contractual conversion[7] Technology Integration - The AI Nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms for ppb-level scent detection sensitivity[8]